Maxlife Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
- Paid Up Capital ₹ 0.15 M
- Company Age 18 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -1238.37%
- Ebitda -2023.61%
- Net Worth -104.33%
- Total Assets -90.04%
About Maxlife Drugs
Maxlife Drugs Private Limited. (MDPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 May 2006 and has a history of 18 years and eight months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Navneet Bhardwaj, Ganga Sharma, Shashi Sharma, and Two other members serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U85121DL2006PTC149174
- Company No.
149174
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 May 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Maxlife Drugs?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Navneet Bhardwaj  | Additional Director | 27-May-2024 | Current |
| Ganga Sharma | Additional Director | 09-Jan-2024 | Current |
| Shashi Sharma | Additional Director | 09-Jan-2024 | Current |
| Ankur Sharma | Additional Director | 09-Jan-2024 | Current |
| Ankit Sharma | Additional Director | 09-Jan-2024 | Current |
Financial Performance of Maxlife Drugs.
Maxlife Drugs Private Limited., for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1238.37% decrease in profit. The company's net worth observed a substantial decline by a decrease of 104.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maxlife Drugs?
Unlock access to Maxlife Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Sharmaa Healthcare Private LimitedGanga Sharma, Shashi Sharma and 2 more are mutual person
- Pushpanjali Creatives Private Limited
Ankur Sharma is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Maxlife Drugs?
Unlock and access historical data on people associated with Maxlife Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maxlife Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maxlife Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
